Published in
Springer, Investigational New Drugs, 4(33), p. 890-894, 2015
DOI: 10.1007/s10637-015-0244-4
Links
Tools
A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer
Journal article published in 2015 by
Zahi Mitri,
Cansu Karakas,
Caimiao Wei,
Brian Briones,
Holly Simmons,
Nuhad Ibrahim,
Ricardo Alvarez,
James L. Murray,
Khandan Keyomarsi 
,
Stacy Moulder
,
Stacy Moulder
This paper is made freely available by the publisher.
Full text: Download
Published version:
archiving forbidden
Data provided by 